For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Global Viral Vector Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the viral vector partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in viral vector partnering including collaboration and licensing deals
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for viral vectors
The report provides a detailed understanding and analysis of how and why companies enter viral vector partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of viral vector outcomes.
This report provides details of the latest viral vector agreements announced in the life sciences since 2016.
The report takes the reader through a comprehensive review viral vector deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering viral vector partnering deals.
The report presents financial deal term values for viral vector deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the viral vector partnering field; both the leading deal values and most active viral vector dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 400 online deal records of actual viral vector deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of viral vector dealmaking.
- Chapter 1 provides an introduction to the report, whilst
- Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016, including details of headline, upfront, milestone and royalty terms.
- Chapter 3 provides a review of the leading viral vector deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
- Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals announded by that company, as well as contract documents, where available.
- Chapter 5 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
- Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by viral vector partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in viral vector partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral vector technologies and products.
Key benefits
Global Viral Vector Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of viral vector deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual viral vector contracts entered into by leading biopharma companies
- Identify most active viral vector dealmakers since 2016
- Insight into terms included in a viral vector partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Viral Vector Partnering Terms and Agreements 2016-2023 is intended to provide the reader with an in-depth understanding and access to viral vector trends and structure of deals entered into by leading companies worldwide.
Viral Vector Partnering Terms and Agreements includes:
- Trends in viral vector dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to viral vector contract documents
- Leading viral vector deals by value since 2016
- Most active viral vector dealmakers since 2016
In Global Viral Vector Partnering Terms and Agreements 2016-2023, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Viral Vector Partnering Terms and Agreements 2016-2023 report provides comprehensive access to available deals and contract documents for over 400 viral vector deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?